PT3848027T - Moduladores de recetores de glicocorticoides de azadecalina fundidas com octa-hidro - Google Patents
Moduladores de recetores de glicocorticoides de azadecalina fundidas com octa-hidroInfo
- Publication number
- PT3848027T PT3848027T PT211582317T PT21158231T PT3848027T PT 3848027 T PT3848027 T PT 3848027T PT 211582317 T PT211582317 T PT 211582317T PT 21158231 T PT21158231 T PT 21158231T PT 3848027 T PT3848027 T PT 3848027T
- Authority
- PT
- Portugal
- Prior art keywords
- receptor modulators
- glucocorticoid receptor
- fused azadecalin
- octahydro fused
- azadecalin glucocorticoid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361908333P | 2013-11-25 | 2013-11-25 | |
| US201461985035P | 2014-04-28 | 2014-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3848027T true PT3848027T (pt) | 2023-05-11 |
Family
ID=53180165
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT211582317T PT3848027T (pt) | 2013-11-25 | 2014-11-21 | Moduladores de recetores de glicocorticoides de azadecalina fundidas com octa-hidro |
| PT14863514T PT3074011T (pt) | 2013-11-25 | 2014-11-21 | Moduladores de receptores de glicocorticoides de azadecalina fundidas com octa-hidro |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT14863514T PT3074011T (pt) | 2013-11-25 | 2014-11-21 | Moduladores de receptores de glicocorticoides de azadecalina fundidas com octa-hidro |
Country Status (20)
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| ES2743620T3 (es) | 2013-11-25 | 2020-02-20 | Corcept Therapeutics Inc | Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro |
| EP3277281B1 (en) | 2015-03-30 | 2022-01-05 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency |
| CA3015218A1 (en) | 2016-03-01 | 2017-09-08 | Corcept Therapeutics, Inc. | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors |
| CN106478464B (zh) * | 2016-08-30 | 2018-06-05 | 黄河三角洲京博化工研究院有限公司 | 一种2-氟-6-三氟甲基苯磺酰氯的制备方法 |
| US9943505B2 (en) * | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
| EP3592358A4 (en) | 2017-03-09 | 2020-12-16 | Corcept Therapeutics, Inc. | USE OF GLUCOCORTICOID RECEPTOR MODULATORS IN TREATMENT OF CATECHOLAMINE SECRETTING TUMORS |
| WO2018183947A1 (en) | 2017-03-31 | 2018-10-04 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat cervical cancer |
| US20180325891A1 (en) * | 2017-05-10 | 2018-11-15 | Corcept Therapeutics, Inc. | Octahydro azadecalin formulations |
| EP3641780B1 (en) | 2017-06-20 | 2025-09-10 | Corcept Therapeutics Incorporated | Treatment of neuroepithelial tumors using selective glucocorticoid receptor modulators |
| WO2019199891A1 (en) * | 2018-04-10 | 2019-10-17 | Duke University | Lasofoxifene treatment of breast cancer |
| CA3098118C (en) | 2018-04-23 | 2023-09-05 | Corcept Therapeutics, Inc. | Methods of preparing regioselective n-alkyl triazoles |
| AR117951A1 (es) | 2018-07-20 | 2021-09-08 | Gruenenthal Gmbh | Derivados de triazolquinoxalina adicionalmente sustituidos |
| IL263184A (en) | 2018-11-21 | 2020-05-31 | Yarden Yosef | Method of treating cancer and compositions for same |
| WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| KR102657097B1 (ko) | 2018-12-19 | 2024-04-15 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 헤테로아릴-케톤 융합 아자데칼린 화합물인 렐라코릴란트를 함유하는 약학적 제제 |
| PH12021552025A1 (en) | 2019-02-22 | 2022-08-22 | Corcept Therapeutics Inc | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
| MX2022004487A (es) | 2019-10-16 | 2022-05-06 | Corcept Therapeutics Inc | Metodo para normalizar el indice de neutrofilos a linfocitos en pacientes con cancer con un antagonista del receptor de glucocorticoide selectivo. |
| KR20220113767A (ko) | 2019-12-11 | 2022-08-16 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 미리코릴란트로 항정신병약-유도 체중 증가를 치료하는 방법 |
| WO2021127376A1 (en) | 2019-12-21 | 2021-06-24 | Corcept Therapeutics Incorporated | Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome |
| AU2021214938B2 (en) | 2020-01-29 | 2024-02-08 | Corcept Therapeutics Incorporated | Treatment of adrenocortical carcinoma with selective glucocorticoid receptor modulators (SGRMs) and antibody checkpoint inhibitors |
| MX2022009781A (es) * | 2020-02-10 | 2022-09-09 | Corcept Therapeutics Inc | Metodos para estimular una respuesta antitumoral utilizando un modulador selectivo del receptor de glucocorticoides. |
| US11787780B2 (en) | 2020-06-22 | 2023-10-17 | Corcept Therapeutics Incorporated | Quaternary indazole glucocorticoid receptor antagonists |
| WO2022134033A1 (en) * | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| WO2022166810A1 (zh) * | 2021-02-03 | 2022-08-11 | 江苏恒瑞医药股份有限公司 | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 |
| US12098144B2 (en) | 2021-12-21 | 2024-09-24 | Corcept Therapeutics Incorporated | Piperazine indazole glucocorticoid receptor antagonists |
| US12098141B2 (en) | 2021-12-21 | 2024-09-24 | Corcept Therapeutics Incorporated | Bicyclic indazole glucocorticoid receptor antagonists |
| US12370188B2 (en) | 2022-10-06 | 2025-07-29 | Corcept Therapeutics Incorporated | Formulations of dazucorilant, a glucocorticoid receptor modulator |
| EP4608402A1 (en) | 2022-10-28 | 2025-09-03 | Corcept Therapeutics Incorporated | Treatments for amyotrophic lateral sclerosis using dazucorilant |
| CN120752040A (zh) * | 2023-02-17 | 2025-10-03 | 科赛普特治疗学股份有限公司 | 用于治疗亨廷顿舞蹈症及其症状的方法和组合物 |
| AU2024275737A1 (en) * | 2023-05-22 | 2025-10-30 | Corcept Therapeutics Incorporated | Methods for treating adrenal gland tumors |
| WO2025152964A1 (en) * | 2024-01-15 | 2025-07-24 | Insilico Medicine Ip Limited | Novel compounds as glucocorticoid receptor modulators and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS322220B1 (cg-RX-API-DMAC7.html) | 1954-11-30 | 1957-04-11 | ||
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| IL72729A (en) | 1983-09-26 | 1988-02-29 | Lilly Co Eli | Trans(+_)octahydropyrazole-ring alkylated pyrazoloquinolines,their preparation and pharmaceutical compositions containing them |
| GB8828669D0 (en) * | 1988-12-08 | 1989-01-11 | Lilly Industries Ltd | Organic compounds |
| JP3160941B2 (ja) | 1991-06-17 | 2001-04-25 | 東レ株式会社 | カルバゾール誘導体および免疫抑制剤 |
| FR2697252B1 (fr) | 1992-10-28 | 1994-12-09 | Fournier Ind & Sante | Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique. |
| JPH09505030A (ja) | 1993-08-06 | 1997-05-20 | スミスクライン・ビーチャム・ソシエタ・ペル・アチオニ | ヒドロイソキノリン誘導体 |
| CA2683097A1 (en) | 1998-03-10 | 1999-09-16 | Research Triangle Institute | Novel opiate compounds, methods of making and methods of use |
| GB9911053D0 (en) | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
| DE60122764T2 (de) * | 2000-11-02 | 2007-10-11 | N.V. Organon | Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen |
| AU2002355929A1 (en) | 2001-07-17 | 2003-03-03 | Smithkline Beecham Corporation | Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same |
| MXPA04000692A (es) * | 2001-07-23 | 2004-04-21 | Corcept Therapeutics Inc | MeTODOS PARA EVITAR GANANCIA DE PESO INDUCIDA ANTISICOTICA. |
| US6679935B2 (en) * | 2001-08-14 | 2004-01-20 | Apex Advanced Technologies, Llc | Lubricant system for use in powdered metals |
| AU2003214879B2 (en) | 2002-01-22 | 2008-02-07 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| AU2004270154A1 (en) | 2003-09-03 | 2005-03-17 | Wyeth | Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same |
| US7678813B2 (en) | 2004-01-09 | 2010-03-16 | Corcept Therapeutics, Inc. | Azadecalin Glucocorticoid receptor modulators |
| AU2005222421B2 (en) * | 2004-03-09 | 2010-09-23 | Corcept Therapeutics, Inc. | Fused ring azadecalin glucocorticoid receptor modulators |
| AU2006232660B2 (en) * | 2005-04-05 | 2010-03-25 | F. Hoffmann-La Roche Ag | 1H-Pyrazole 4-Carboxylamides, their preparation and their use as 11Beta-hydroxysteroid dehydrogenase |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| WO2009058944A2 (en) * | 2007-11-01 | 2009-05-07 | Bristol-Myers Squibb Company | Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and /or nf- kappa b activity and use thereof |
| EP2247597A1 (en) * | 2008-02-07 | 2010-11-10 | Bristol-Myers Squibb Company | Fused heteroaryl modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof |
| CN102421437B (zh) | 2009-05-12 | 2014-03-19 | 科赛普特治疗公司 | 固体形式和制备方法 |
| US8710035B2 (en) * | 2010-03-24 | 2014-04-29 | The University Of Chicago | Methods and compositions related to glucocorticoid receptor antagonists and breast cancer |
| US8598154B2 (en) * | 2010-08-27 | 2013-12-03 | Corcept Therapeutics, Inc. | Pyridyl-amine fused azadecalin modulators |
| AU2012204232A1 (en) | 2011-01-07 | 2013-06-27 | Corcept Therapeutics, Inc. | Combination steroid and glucocorticoid receptor antagonist therapy |
| WO2013130420A1 (en) | 2012-02-27 | 2013-09-06 | Corcept Therapeutics, Inc. | Phenyl heterocycloalkyl glucocorticoid receptor modulators |
| KR102062640B1 (ko) * | 2012-05-25 | 2020-01-06 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 헤테로아릴-케톤 융합된 아자데칼린 글루코코르티코이드 수용체 조절제 |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| ES2743620T3 (es) | 2013-11-25 | 2020-02-20 | Corcept Therapeutics Inc | Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro |
| US9943505B2 (en) * | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
-
2014
- 2014-11-21 ES ES14863514T patent/ES2743620T3/es active Active
- 2014-11-21 PL PL21158231.7T patent/PL3848027T3/pl unknown
- 2014-11-21 ES ES21158231T patent/ES2943542T3/es active Active
- 2014-11-21 DK DK21158231.7T patent/DK3848027T3/da active
- 2014-11-21 PT PT211582317T patent/PT3848027T/pt unknown
- 2014-11-21 EP EP14863514.7A patent/EP3074011B1/en active Active
- 2014-11-21 PT PT14863514T patent/PT3074011T/pt unknown
- 2014-11-21 US US14/549,885 patent/US10047082B2/en active Active
- 2014-11-21 EP EP23157691.9A patent/EP4219494A1/en active Pending
- 2014-11-21 ES ES19177963T patent/ES2869172T3/es active Active
- 2014-11-21 PL PL14863514T patent/PL3074011T3/pl unknown
- 2014-11-21 CA CA2931302A patent/CA2931302C/en active Active
- 2014-11-21 DK DK14863514.7T patent/DK3074011T3/da active
- 2014-11-21 MX MX2016006725A patent/MX368167B/es active IP Right Grant
- 2014-11-21 RU RU2016123449A patent/RU2674983C1/ru active
- 2014-11-21 EP EP21158231.7A patent/EP3848027B1/en active Active
- 2014-11-21 AU AU2014352915A patent/AU2014352915B2/en active Active
- 2014-11-21 EP EP19177963.6A patent/EP3560493B1/en active Active
- 2014-11-21 KR KR1020167017023A patent/KR102352737B1/ko active Active
- 2014-11-21 WO PCT/US2014/066759 patent/WO2015077530A1/en not_active Ceased
- 2014-11-21 BR BR112016011826-0A patent/BR112016011826B1/pt active IP Right Grant
- 2014-11-21 FI FIEP21158231.7T patent/FI3848027T3/fi active
- 2014-11-21 JP JP2016533614A patent/JP6516743B2/ja active Active
- 2014-11-21 MY MYPI2016000978A patent/MY180141A/en unknown
- 2014-11-21 CN CN201910143177.XA patent/CN109761976B/zh active Active
- 2014-11-21 CN CN201480074087.5A patent/CN106029066B/zh active Active
- 2014-11-21 PL PL19177963T patent/PL3560493T3/pl unknown
-
2016
- 2016-05-24 PH PH12016500968A patent/PH12016500968B1/en unknown
- 2016-05-25 IL IL245848A patent/IL245848B/en active IP Right Grant
- 2016-06-14 ZA ZA2016/04026A patent/ZA201604026B/en unknown
-
2017
- 2017-10-25 JP JP2017206081A patent/JP2018012734A/ja active Pending
-
2018
- 2018-07-16 US US16/036,001 patent/US20190135805A1/en not_active Abandoned
- 2018-10-16 US US16/161,642 patent/US10323034B2/en active Active
-
2019
- 2019-03-28 JP JP2019063279A patent/JP2019094355A/ja not_active Withdrawn
- 2019-04-12 US US16/382,474 patent/US10787449B2/en active Active
-
2020
- 2020-08-04 US US16/984,914 patent/US11370789B2/en active Active
-
2021
- 2021-01-12 US US17/146,608 patent/US11560379B2/en active Active
- 2021-02-15 JP JP2021021630A patent/JP2021073315A/ja not_active Withdrawn
-
2022
- 2022-11-28 JP JP2022189246A patent/JP2023011052A/ja not_active Withdrawn
- 2022-12-09 US US18/078,389 patent/US12139486B2/en active Active
-
2024
- 2024-08-30 JP JP2024148322A patent/JP2024170470A/ja active Pending
- 2024-10-04 US US18/906,346 patent/US20250034140A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201604026B (en) | Octahydro fused azadecalin glucocorticoid receptor modulators | |
| IL235868A0 (en) | Substances containing heteroaryl-ketone-conjugated azadecline and preparations containing them for use as glucocorticoid receptor modulators | |
| ZA201605712B (en) | Therapeutic combinations with estrogen receptor modulators | |
| EP2970130A4 (en) | MODULATORS OF POLYCYCLIC STROGEN RECEPTORS AND USES THEREOF | |
| IL246177A0 (en) | Tetrahydropyridopyrazines as gpr6 modulators | |
| IL242782B (en) | cxcr7 receptor modulators | |
| IL239076A0 (en) | Novel and selective androgen receptor modulators | |
| GB201320091D0 (en) | Selective glucocorticoid receptor ligands | |
| GB201301896D0 (en) | Novel Estrogen Receptor Ligands |